122 related articles for article (PubMed ID: 38657403)
21. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
Richardson TL; Halvorson AE; Hackstadt AJ; Hung AM; Greevy R; Grijalva CG; Elasy TA; Roumie CL
Ann Intern Med; 2023 Jun; 176(6):751-760. PubMed ID: 37155984
[TBL] [Abstract][Full Text] [Related]
22. Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real-World Evidence From an International Collaborative Database.
Anson M; Malik A; Zhao SS; Austin P; Ibarburu GH; Jaffar S; Garrib A; Cuthbertson DJ; Alam U
J Diabetes Res; 2024; 2024():3470654. PubMed ID: 38846063
[No Abstract] [Full Text] [Related]
23. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved.
Thiele RG; Schlesinger N
Rheumatol Int; 2010 Feb; 30(4):495-503. PubMed ID: 19543895
[TBL] [Abstract][Full Text] [Related]
24. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
25. Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.
D'Andrea E; Wexler DJ; Kim SC; Paik JM; Alt E; Patorno E
JAMA Intern Med; 2023 Mar; 183(3):242-254. PubMed ID: 36745425
[TBL] [Abstract][Full Text] [Related]
26. Risk of Severe Hypoglycemia With Newer Second-line Glucose-lowering Medications in Older Adults With Type 2 Diabetes Stratified by Known Indicators of Hypoglycemia Risk.
Htoo PT; Paik JM; Alt E; Kim DH; Wexler DJ; Kim SC; Patorno E
J Gerontol A Biol Sci Med Sci; 2023 Dec; 78(12):2426-2434. PubMed ID: 36866496
[TBL] [Abstract][Full Text] [Related]
27. Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis.
Lai SW; Hwang BF; Kuo YH; Liu CS; Liao KF
Front Endocrinol (Lausanne); 2023; 14():1158153. PubMed ID: 37288295
[TBL] [Abstract][Full Text] [Related]
28. Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study.
Chen TH; Li YR; Chen SW; Lin YS; Sun CC; Chen DY; Mao CT; Wu M; Chang CH; Chu PH; Wu VC
Cardiovasc Diabetol; 2020 Nov; 19(1):189. PubMed ID: 33167990
[TBL] [Abstract][Full Text] [Related]
29. Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis.
Banerjee M; Pal R; Mukhopadhyay S
Acta Diabetol; 2022 Jun; 59(6):783-791. PubMed ID: 35249140
[TBL] [Abstract][Full Text] [Related]
30. Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006-2020.
Liaw J; Harhay M; Setoguchi S; Gerhard T; Dave CV
Diabetes Care; 2022 Oct; 45(10):2316-2325. PubMed ID: 35984049
[TBL] [Abstract][Full Text] [Related]
31. Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.
Helget LN; O'Dell JR; Newcomb JA; Androsenko M; Brophy MT; Davis-Karim A; England BR; Ferguson R; Pillinger MH; Neogi T; Palevsky PM; Wu H; Kramer B; Mikuls TR
Arthritis Rheumatol; 2024 Apr; 76(4):638-646. PubMed ID: 37842953
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
33. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
34. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers.
Yang JY; Wang T; Pate V; Gower EW; Crowley MJ; Buse JB; Stürmer T
Diabetes Obes Metab; 2019 May; 21(5):1223-1236. PubMed ID: 30697897
[TBL] [Abstract][Full Text] [Related]
35. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
[TBL] [Abstract][Full Text] [Related]
36. Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.
Lemke A; Brokmeier HM; Leung SB; Mara KC; Mour GK; Wadei HM; Hill JM; Stegall M; Kudva YC; Shah P; Kukla A
Clin Transplant; 2022 Aug; 36(8):e14718. PubMed ID: 35593882
[TBL] [Abstract][Full Text] [Related]
37. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
38. Burden and management of gout in a multi-ethnic Asian cohort.
Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
[TBL] [Abstract][Full Text] [Related]
39. Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes.
Paik JM; Tesfaye H; Curhan GC; Zakoul H; Wexler DJ; Patorno E
JAMA Intern Med; 2024 Mar; 184(3):265-274. PubMed ID: 38285598
[TBL] [Abstract][Full Text] [Related]
40. Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.
Dalbeth N; House ME; Horne A; Petrie KJ; McQueen FM; Taylor WJ
BMC Musculoskelet Disord; 2012 Sep; 13():174. PubMed ID: 22978848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
